[Comparison of curative effect of autologous peripheral blood stem cell transplantation versus bone marrow transplantation for acute leukemia]. 2003

Yi-Zhuo Zhang, and Bo-Long Zhang, and Shan-Qian Yao, and Hai-Chuan Liu, and Fang-Ding Lou, and Chun-Ji Gao, and Xiao-Ping Han, and Xiao-Xiong Wu, and Yu Zhao, and Quan-Shun Wang, and Yu Jing, and Miao Zhang, and Hai-Jie Jin, and Zi-Jiang Shi, and Wan-Ming Da
Department of Hematology, General Hospital of Chinese PLA, Beijing 100853. zhangyz8123@sina.com

To compare the clinical outcome of autologous peripheral blood stem cell transplantation (APBSCT) and autologous bone marrow transplantation (ABMT) in treatment of patients with acute leukemia in first remission, 41 patients received APBSCT, 17 patients received unpurged ABMT and 30 patients received purged ABMT. The results showed that hematopoietic recovery was significantly earlier after APBSCT than that after purged or unpurged ABMT. The 3-year disease-free survival (DFS), relapse rate (RR) and transplant-related mortality (TRM) for all patients of 3 groups were 51.7%, 41.7% and 6.8%, respectively. DFS and RR were significantly influenced by disease types (ALL or AML) and intervals between diagnosis and CR(1) or CR(1) and transplant. The main causes of transplant-related death were infection and hemorrhage. After APBSCT, DFS, RR and TRM were 48.4%, 43.9% and 4.9%, respectively, and did not differ significantly from those found in unpurged ABMT (47.1%, 45.6% and 11.8%) or purged ABMT (66.5%, 29.6% and 6.7%). It is concluded that the clinical outcome of APBSCT is similar to unpurged or purged ABMT but APBSCT allows faster recovery of hematopoiesis and needs less transfusion support.

UI MeSH Term Description Entries
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D007948 Leukemia, Monocytic, Acute An acute myeloid leukemia in which 80% or more of the leukemic cells are of monocytic lineage including monoblasts, promonocytes, and MONOCYTES. Leukemia, Monoblastic, Acute,Leukemia, Myeloid, Acute, M5,Leukemia, Myeloid, Schilling-Type,Monoblastic Leukemia, Acute,Monocytic Leukemia, Acute,Myeloid Leukemia, Acute, M5,Myeloid Leukemia, Schilling-Type,Leukemia, Acute Monocytic,Leukemia, Myeloid, Schilling Type,Acute Monoblastic Leukemia,Acute Monoblastic Leukemias,Acute Monocytic Leukemia,Acute Monocytic Leukemias,Leukemia, Schilling-Type Myeloid,Leukemias, Acute Monoblastic,Leukemias, Acute Monocytic,Monoblastic Leukemias, Acute,Monocytic Leukemias, Acute,Myeloid Leukemia, Schilling Type,Schilling-Type Myeloid Leukemia
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D004915 Leukemia, Erythroblastic, Acute A myeloproliferative disorder characterized by neoplastic proliferation of erythroblastic and myeloblastic elements with atypical erythroblasts and myeloblasts in the peripheral blood. Di Guglielmo's Disease,Erythremic Myelosis,Erythroblastic Leukemia, Acute,Erythroleukemia,Leukemia, Myeloid, Acute, M6,Myeloid Leukemia, Acute, M6,Di Guglielmo Disease,Acute Erythroblastic Leukemia,Acute Erythroblastic Leukemias,Di Guglielmos Disease,Disease, Di Guglielmo,Disease, Di Guglielmo's,Erythremic Myeloses,Erythroblastic Leukemias, Acute,Erythroleukemias,Leukemia, Acute Erythroblastic,Leukemias, Acute Erythroblastic,Myeloses, Erythremic,Myelosis, Erythremic
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup

Related Publications

Yi-Zhuo Zhang, and Bo-Long Zhang, and Shan-Qian Yao, and Hai-Chuan Liu, and Fang-Ding Lou, and Chun-Ji Gao, and Xiao-Ping Han, and Xiao-Xiong Wu, and Yu Zhao, and Quan-Shun Wang, and Yu Jing, and Miao Zhang, and Hai-Jie Jin, and Zi-Jiang Shi, and Wan-Ming Da
January 1993, Lancet (London, England),
Yi-Zhuo Zhang, and Bo-Long Zhang, and Shan-Qian Yao, and Hai-Chuan Liu, and Fang-Ding Lou, and Chun-Ji Gao, and Xiao-Ping Han, and Xiao-Xiong Wu, and Yu Zhao, and Quan-Shun Wang, and Yu Jing, and Miao Zhang, and Hai-Jie Jin, and Zi-Jiang Shi, and Wan-Ming Da
January 1992, Bone marrow transplantation,
Yi-Zhuo Zhang, and Bo-Long Zhang, and Shan-Qian Yao, and Hai-Chuan Liu, and Fang-Ding Lou, and Chun-Ji Gao, and Xiao-Ping Han, and Xiao-Xiong Wu, and Yu Zhao, and Quan-Shun Wang, and Yu Jing, and Miao Zhang, and Hai-Jie Jin, and Zi-Jiang Shi, and Wan-Ming Da
January 1991, Bone marrow transplantation,
Yi-Zhuo Zhang, and Bo-Long Zhang, and Shan-Qian Yao, and Hai-Chuan Liu, and Fang-Ding Lou, and Chun-Ji Gao, and Xiao-Ping Han, and Xiao-Xiong Wu, and Yu Zhao, and Quan-Shun Wang, and Yu Jing, and Miao Zhang, and Hai-Jie Jin, and Zi-Jiang Shi, and Wan-Ming Da
May 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Yi-Zhuo Zhang, and Bo-Long Zhang, and Shan-Qian Yao, and Hai-Chuan Liu, and Fang-Ding Lou, and Chun-Ji Gao, and Xiao-Ping Han, and Xiao-Xiong Wu, and Yu Zhao, and Quan-Shun Wang, and Yu Jing, and Miao Zhang, and Hai-Jie Jin, and Zi-Jiang Shi, and Wan-Ming Da
November 1997, Bone marrow transplantation,
Yi-Zhuo Zhang, and Bo-Long Zhang, and Shan-Qian Yao, and Hai-Chuan Liu, and Fang-Ding Lou, and Chun-Ji Gao, and Xiao-Ping Han, and Xiao-Xiong Wu, and Yu Zhao, and Quan-Shun Wang, and Yu Jing, and Miao Zhang, and Hai-Jie Jin, and Zi-Jiang Shi, and Wan-Ming Da
December 2011, Blood,
Yi-Zhuo Zhang, and Bo-Long Zhang, and Shan-Qian Yao, and Hai-Chuan Liu, and Fang-Ding Lou, and Chun-Ji Gao, and Xiao-Ping Han, and Xiao-Xiong Wu, and Yu Zhao, and Quan-Shun Wang, and Yu Jing, and Miao Zhang, and Hai-Jie Jin, and Zi-Jiang Shi, and Wan-Ming Da
December 1996, Bone marrow transplantation,
Yi-Zhuo Zhang, and Bo-Long Zhang, and Shan-Qian Yao, and Hai-Chuan Liu, and Fang-Ding Lou, and Chun-Ji Gao, and Xiao-Ping Han, and Xiao-Xiong Wu, and Yu Zhao, and Quan-Shun Wang, and Yu Jing, and Miao Zhang, and Hai-Jie Jin, and Zi-Jiang Shi, and Wan-Ming Da
January 2009, Hematology/oncology and stem cell therapy,
Yi-Zhuo Zhang, and Bo-Long Zhang, and Shan-Qian Yao, and Hai-Chuan Liu, and Fang-Ding Lou, and Chun-Ji Gao, and Xiao-Ping Han, and Xiao-Xiong Wu, and Yu Zhao, and Quan-Shun Wang, and Yu Jing, and Miao Zhang, and Hai-Jie Jin, and Zi-Jiang Shi, and Wan-Ming Da
March 1991, Haematologica,
Yi-Zhuo Zhang, and Bo-Long Zhang, and Shan-Qian Yao, and Hai-Chuan Liu, and Fang-Ding Lou, and Chun-Ji Gao, and Xiao-Ping Han, and Xiao-Xiong Wu, and Yu Zhao, and Quan-Shun Wang, and Yu Jing, and Miao Zhang, and Hai-Jie Jin, and Zi-Jiang Shi, and Wan-Ming Da
June 1999, Bone marrow transplantation,
Copied contents to your clipboard!